Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

Elderly dengue patients face more difficult platelet recovery

Tristan Manalac
25 Oct 2019
Researchers discovered that children infected with dengue for the second time were found to be prone to severe forms of dengue when antibodies in their blood were present at specific levels.

Old age and lower white cell counts are significant risk factors for poor platelet recovery among dengue patients with thrombocytopaenia, according to a recent Singapore study.

“[W}e identified several independent predictors of poor platelet recovery in dengue patients,” said researchers, noting that their findings highlight “the impact of ageing and, potentially, immunosenescence in dengue infection.”

Of 362 participating dengue patients, 188 were randomly assigned to prophylactic platelet transfusion, while 181 received supportive care alone. Nine patients did not have day 2 platelet counts and were excluded. Of the remaining 360 patients, 43.9 percent (n=158) had poor platelet recovery, defined as having a platelet count of 20,000/µL by day 2. [Clin Infect Dis 2019;doi:10.1093/cid/ciz850]

Analysis according to treatment groups showed that most of the patients with poor platelet recovery did not receive a platelet transfusion (56.3 percent vs 32.3 percent).

In unadjusted analysis, age (p=0.0076), white cell counts (p=0.0007), serum creatinine (p=0.0108) and the number of days with illness at study enrolment (p=0.0002) were identified as significant predictors of poor platelet recovery.

After controlling for transfusion, only age (adjusted odds ratio [OR], 1.03, 95 percent CI, 1.01–1.05; p=0.0041), white cell count (adjusted OR, 0.79, 0.70–0.90; p=0.0002) and day of illness at study entry (adjusted OR, 0.67, 0.53–0.85; p=0.0009) remained significant risk factors for poor recovery.

“Although thrombocytopaenia and platelet dysfunction have been well described in dengue, the pathophysiology has not been well studied,” said the researchers. Some proposed mechanisms included peripheral platelet destruction, platelet sequestration and virus-induced bone marrow suppression. [Viral Immunol 2006;19:127-132; Am J Trop Med Hyg 2002;66:435-441; Blood 1989;74:1235-1240]

This was further complicated in older patients, who had been shown to suffer from greater disease severities and atypical presentations. Immunosenescence might help account for these. [PLoS Negl Trop Dis 2014;8:e2777]

“Immunosenescence in the older population may result in poorer bone marrow and other physiological reserves, which may account for the poor platelet recovery observed in this analysis in the older age group,” the researchers said.

The present study was a posthoc analysis of the Adult Dengue Platelet (ADEPT) study, an open-label, randomized trial conducted on patients in Singapore and Malaysia. The current study sample comprised the as-treated population in the original trial with available day 2 platelet count data.

“This time point was chosen following the observation in ADEPT that 25.3 percent of patients required a second transfusion to maintain a platelet count above 20 000 per μL on Day 2, but no patients required transfusion on subsequent days,” the researchers explained.

“Further work is needed to examine the pathophysiology and role of thrombocytopaenia and the risk of clinical bleeding in severe dengue,” they said. “Further studies evaluating the role of platelet transfusions in patients with severe dengue will be valuable, but sample sizes may be hard to attain.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.